Mesoblast Financial Results and Corporate Update Webcast

On August 24, 2026, Mesoblast Limited, a leading global company specializing in allogeneic cellular medicines for inflammatory conditions and listed on ASX under the symbol MSB and Nasdaq under MESO, will be conducting a webcast to review operational achievements and financial outcomes for the complete year closing on June 30, 2026.